Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

0.1718 -0.0081 (-4.50%)
Streaming Delayed Price Updated: 2:28 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens
Via ACCESSWIRE
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th
Via ACCESSWIRE
Why NeuroBo Pharmaceuticals Is Trading Higher By Around 55%; Here Are 25 Stocks Moving Premarket
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) rose 54.6% to $26.07 in pre-market trading after the company entered into an exclusive license agreement with Dong-A. 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials
Via ACCESSWIRE
Jaguar Health to Host Investor Webcast Monday, August 22nd at 8:30 AM Eastern Time Regarding Q2 2022 Financials & Corporate Updates
Via ACCESSWIRE
Jaguar Health Seeks FDA Nod For Cholera Candidate Study
Jaguar Health (NASDAQ: JAGX) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its subsidiary Napo's NP-300 drug product candidate for the... 
Via Benzinga
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Via ACCESSWIRE
Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
Via ACCESSWIRE
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Looking Into Jaguar Health's Return On Capital Employed
According to Benzinga Pro data, during Q2, Jaguar Health (NASDAQ:JAGX) posted sales of $2.92 million. Earnings were up 48.3%, but Jaguar Health still reported an overall loss of $9.39 million. 
Via Benzinga
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review
Via ACCESSWIRE
Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea
Via ACCESSWIRE
Short Volatility Alert: Jaguar Health, Inc.
On Friday, shares of Jaguar Health, Inc. (NASDAQ: JAGX) experienced volatile short activity. After the activity, the stock price went up +4.83% to $0.3082. The overall sentiment for JAGX has been... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.8% to $0.97 during Monday's after-market session. The company's market cap stands at $31.6 million. 
Via Benzinga
Earnings Scheduled For August 22, 2022
Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is estimated to report quarterly loss at $0.22 per share on revenue of $3.10 million. 
Via Benzinga
Jaguar Health's Earnings: A Preview
Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Monday, 2022-08-22. Here's what investors need to know before the announcement. Analysts estimate that Jaguar Health... 
Via Benzinga
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
Via ACCESSWIRE
Gallup Survey Estimates Nearly 30 Million U.S. Dog Owners Have Experienced Canine Cancer, with Many Saying it Negatively Impacted Their Own Quality of Life
Via ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1. 
Via Benzinga
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions
Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / July 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 27, 2022, the Company granted 60,000 restricted stock... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China
License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months 
From Jaguar Health, Inc.
Via AccessWire
Could This Company's Gastrointestinal Drug Be A Powerful Pill For People And Animals With Chronic, Debilitating Diarrhea?
San Francisco-based Jaguar Health, Inc. (NASDAQ: JAGX), a commercial-stage pharmaceuticals company, says it is focused on developing novel, plant-based, non-opioid and sustainably derived prescription... 
Via Benzinga
Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi
SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr. Mohamad Miqdady on short bowel syndrome (SBS) at the Elite Ped-GI Congress,... 
From Jaguar Health, Inc.
Via AccessWire
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. 
Via Benzinga
Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1
Canalevia®-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.